Taraxasterol

Taraxasterol: A Comprehensive Encyclopedic Reference

1. Identity: Chemical Nature, Botanical Source, and Common Forms

1.1 Chemical Identity

Taraxasterol, also known as (3β, 18α, 19α)-Urs-20(30)-en-3-ol, is a pentacyclic triterpene with a 1,2-cyclopentene phenanthrene structure. The molecular formula of taraxasterol is C₃₀H₅₀O, and its molecular weight and melting point are 426.72 g/mol and 221–222°C, respectively. The compound is classified within the lupane-related subgroup of pentacyclic triterpenoids and is sometimes referred to by the synonym anthesterin. Taraxasterol is a triterpene derived from the mevalonate pathway and is found in dandelions; its biosynthetic precursor is squalene.

In the first step of its biosynthetic formation, squalene is cyclized with molecular oxygen, FAD, and NADPH via the enzyme squalene epoxidase—a flavoprotein—to yield (2S)-2,3-oxidosqualene. In the second step, if the oxidosqualene is folded in the chair conformation within the enzyme, a cascade of cyclizations occurs that results in the formation of the dammarenyl cation, which is then subjected to an alkyl shift to create a six-membered ring and relieve ring strain to form the baccharenyl cation.

Among the compounds identified and separated from Taraxaci herba, taraxasterol and taraxasteryl acetate are found alongside chicoric acid, chlorogenic acid, isorhamnetin, and luteolin, and are considered responsible for anti-inflammatory, antioxidant, antibacterial, anti-tumor, and anti-cancer activities. The acetate ester form—taraxasteryl acetate (C₃₂H₅₂O₂)—is a naturally occurring derivative that co-occurs with the free alcohol in dandelion tissues and has been investigated independently for its biological activity.

1.2 Botanical Source

Taraxasterol is a pentacyclic triterpenoid that was first discovered from the roots of Taraxacum officinale, and is generally found in the Taraxacum genus (called Pugongying in Chinese). Dandelion is a member of the family Asteraceae and is widely distributed in the warmer temperate zones of the Northern Hemisphere.

The genus Taraxacum in the family Asteraceae includes T. mongolicum, T. sinicum Kitag, and several plants of the same genus, and the whole grass is used medicinally. The genus Taraxacum, commonly known as dandelions, has been utilized as a food source and medicinal herb for centuries across Asia, North America, and Europe. The Korean Herbal Pharmacopoeia recognizes the whole plants of Taraxacum platycarpum, T. officinale, T. mongolicum, and T. coreanum (of the Compositae family) as Taraxaci Herba.

Taraxasterol is not exclusive to the dandelion genus. Primarily sourced from Asteraceae family herbs such as the dandelion, taraxasterol is a pentacyclic triterpenoid found across this plant family. Taraxastane-type triterpenoids have also been reported from species such as Saussurea petrovii and other Asteraceae members, and taraxasterol has been identified in lettuce (Lactuca sativa), which belongs to the same tribe (Lactuceae) as dandelion.

1.3 Common Forms and Preparations

As a dietary supplement or research ingredient, taraxasterol is commercially available as an isolated purified compound, typically as a white to off-white crystalline powder, often with a stated purity of ≥98%. In published experimental research, taraxasterol of purity greater than 98% is available from chemical suppliers such as Chengdu Preferred Biotechnology Co., Ltd. The compound also occurs naturally in whole-plant dandelion preparations including dried herb, root extract, and leaf extract, all of which are common commercial forms. Traditional preparations include fresh and dried raw materials used to make extracts, tinctures, decoctions, infusions, wrap compresses, syrups, and even wine or coffee substitutes.

2. Traditional and Historical Use

2.1 Arabian and Early Medieval Medicine

The dandelion plant has long been used as a medicinal herb. Its therapeutic role was mentioned as early as the 10th and 11th centuries by Arabian physicians for the treatment of liver and spleen diseases. It is important to note that these historical practitioners did not isolate taraxasterol as a specific compound; rather, they used preparations from the whole plant, and the triterpenoid content—including taraxasterol—was among the active constituents presumed responsible for the observed effects.

2.2 Traditional Chinese Medicine

In traditional Chinese medicine, dandelion is used in combination with other herbs to treat hepatitis and enhance the immune response to upper respiratory tract infections, bronchitis, and pneumonia. In East Asia, Taraxaci Herba has been employed to treat inflammatory disorders such as infectious skin diseases and appendicitis since its documentation in the Tang Materia Medica (also known as the Newly Revised Materia Medica), the world's first pharmacopoeia, published during the Tang Dynasty in China in 659 AD.

In China, dandelion has been used historically to relieve swelling, reduce toxins from the body, and promote lactation. Taraxacum officinale (L.) Weber ex F.H.Wigg has long been traditionally used as a kind of Chinese herbal medicine for disorders of the liver, breast, and gallbladder as well as hepatitis and digestive diseases.

2.3 European Folk Medicine

In the traditional societies of Central-Eastern Europe, dandelion is a source of both food and medicinal raw materials, and growing interest in the medicinal properties of dandelion herbal preparations has encouraged focus on their use in traditional folk medicine of Central-Eastern European communities. Historically, dandelion use has been documented in folk and traditional medicine for the treatment of various issues including inflammation, digestive issues, gynecological issues, and skin diseases.

In Turkish popular medicine, plants of the genus Taraxacum are used as antirheumatic, anti-inflammatory, and anti-diabetic medicines, and for the treatment of eye diseases, stomach disorders, and kidney stones.

2.4 Traditional Preparations

Apart from being used as a pharmaceutical, the inflorescences, leaves, and roots of Taraxacum species are processed into different food products. Young leaves of cultivated or wild species are consumed fresh as salad, whereas the roots are roasted and utilized as a coffee substitute. Additionally, the extracts are used as flavor components in various food products, including alcoholic beverages and soft drinks, frozen dairy desserts, candy, baked goods, gelatins and puddings, and cheese.

The variety of ways to prepare the raw material is noteworthy; fresh and dried raw materials were used to make extracts, tinctures, decoctions, infusions, wrap compresses, syrups, and even wine or coffee substitutes, with the mentioned preparations prepared individually for particular ailments.

3. Phytochemistry and Co-occurring Compounds

Previous phytochemical investigations have shown that Taraxacum species contain sesquiterpene lactones, triterpenes, phytosterols, flavonoids, lignans, coumarins, phenolic acids, beta-carboline alkaloids, indole alkaloids, and carotenoids. Recent studies have highlighted the potential pharmacological effects of dandelion attributed to a rich phytochemical profile containing flavonoids, terpenoids, phenolic acids, polysaccharides, and sterols.

Taraxasterol exists in dandelion tissue alongside a number of structurally related and pharmacologically relevant compounds. Key bioactive compounds such as taraxasterol, chlorogenic acid, chicoric acid, and taraxinic acid have been identified as promising agents capable of inhibiting tumor cell proliferation and modulating oncogenic pathways. Terpenoids such as taraxasterol, β-amyrin, and lupeol, commonly found in the aerial parts and roots of dandelion, have been reported to exhibit anti-inflammatory, anticancer, and analgesic effects.

The structure and configuration of taraxasterol were first fully reported in the 1950s. Since that time, taraxasterol has been the subject of increasing pharmacological investigation, particularly from approximately 2010 onwards, with the bulk of mechanistic research emerging in the period 2013–2024.

4. Mechanisms of Action

4.1 Anti-inflammatory Mechanisms

Taraxasterol impacts several aspects of inflammatory action. On the one hand, taraxasterol reduces the levels of inflammatory cytokines, including TNF-α and IL-6, and reduces serum levels of inflammatory mediators NO and PGE₂ through inhibiting NF-κB and MAPK signaling pathways.

Taraxasterol has been reported to inhibit iNOS and COX-2 expression in LPS-stimulated RAW264.7 cells. Taraxasterol also inhibited IL-1β-induced NO and PGE₂ production in human osteoarthritic chondrocytes.

In microglia—brain-resident immune cells—a distinct mechanistic axis has been characterized. Taraxasterol dose-dependently inhibited LPS-induced TNF-α and IL-1β production and NF-κB activation. Taraxasterol also disrupted the formation of lipid rafts and inhibited translocation of TLR4 into lipid rafts. Furthermore, taraxasterol was found to activate the LXRα–ABCA1 signaling pathway, which induces cholesterol efflux from cells, and the anti-inflammatory effect of taraxasterol was attenuated by transfection with LXRα siRNA.

In the context of rheumatoid arthritis synoviocytes, taraxasterol was reported to suppress the NOD-like receptor protein 3 (NLRP3) inflammasome through inhibition of the expression of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and caspase-1, within a dose range of 0.3 to 0 μm in HFLS-RA cells and with 10 mg/kg in collagen-induced arthritis (CIA) mice.

4.2 Antioxidant Mechanisms

Taraxasterol effectively alleviated the depletion of glutathione (GSH), the increase in lipid peroxidation of malondialdehyde (MDA), the reduction in total superoxide dismutase (T-SOD) activity, and the decrease in total antioxidant capacity (T-AOC). Taraxasterol further reduced the accumulation of reactive oxygen species (ROS).

In liver cells exposed to acetaminophen (APAP), taraxasterol increased the activity of antioxidants, inhibited the production of peroxides, and reduced inflammatory response and apoptosis in vitro and in vivo. Taraxasterol promoted Nrf2 and HO-1 expression, suppressed JNK phosphorylation, and decreased the Bax/Bcl-2 ratio and caspase-3 expression in AML12 cells and mice.

4.3 Anticancer Mechanisms

In non-small cell lung cancer cell lines, taraxasterol inhibited the proliferation of cells by inducing S-phase cell cycle arrest and prevented cell migration by interfering with epithelial-mesenchymal transition (EMT). Pharmacological network analysis predicted that induction of apoptosis might be the potential mechanism of taraxasterol-mediated cell death. Further in vitro experiments showed that taraxasterol could significantly induce cancer cell apoptosis as verified by increased pro-apoptotic molecules including Bax, caspase-9, and PARP1, downregulated anti-apoptotic protein Bcl-2, and decreased mitochondrial potential.

Accumulating evidence shows that taraxasterol exerts antitumor effects through several signaling pathways including Wnt/β-catenin and PI3K/Akt. Five collective targets of taraxasterol and gastric cancer were identified including epidermal growth factor receptor (EGFR), matrix metalloproteinase 2 (MMP2), B-Raf proto-oncogene serine/threonine kinase (BRAF), fibroblast growth factor receptor 2 (FGFR2), and AKT serine/threonine kinase 1 (AKT1).

Taraxasterol inhibits papillary thyroid cancer cell migration and prevents epithelial-mesenchymal transition (EMT) induced by TGF-β by decreasing the expression of matrix metalloproteinases MMP-2 and MMP-9 and blocking the Wnt/β-catenin signaling pathway.

5. Scientific Evidence by Health Area

Important note on evidence quality: The overwhelming majority of published studies on taraxasterol are conducted in cell cultures (in vitro) or in rodent animal models (in vivo). More animal and clinical studies are also required on the metabolism, bioavailability, and safety of taraxasterol to support its applications in pharmaceuticals and medicine. As of the most recent systematic reviews (2022–2024), no completed, published randomized controlled trials (RCTs) in human subjects specifically evaluating isolated taraxasterol have been identified in the peer-reviewed literature. Evidence strength is characterized accordingly throughout this section.

5.1 Inflammation and Inflammatory Disease

Evidence strength: Preclinical (in vitro and animal); no human RCT data.

One study aimed to determine the in vivo anti-inflammatory effects of taraxasterol against animal models. Anti-inflammatory effects were assessed in four animal models using dimethylbenzene-induced mouse ear edema, carrageenan-induced rat paw edema, acetic acid-induced mouse vascular permeability, and cotton pellet-induced rat granuloma tests. The results demonstrated that taraxasterol dose-dependently attenuated dimethylbenzene-induced mouse ear edema and carrageenan-induced rat paw edema, decreased acetic acid-induced mouse vascular permeability, and inhibited cotton pellet-induced rat granuloma formation.

Earlier work showed that taraxasterol has anti-inflammatory activity in vitro by regulating proinflammatory cytokine and mediator production through suppressing NF-κB and MAPK signaling pathways.

In the endotoxic shock model, after 36 hours of treatment with taraxasterol at doses of 2.5, 5, and 10 mg/kg, survival rates in LPS-induced endotoxic shock mouse models were up to 30%, 40%, and 70%, respectively. Moreover, no toxic effects of taraxasterol were observed in mice that received doses as high as 10 mg/kg.

An early reference study established a useful index: Akihisa et al. demonstrated that the ID₅₀ of taraxasterol extracted from Compositae flowers was 0.3 mg/ear on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice.

5.2 Arthritis (Rheumatoid and Osteoarthritis)

Evidence strength: Preclinical (cell culture and rodent models); no human clinical data.

Wang et al. studied the protective effect of taraxasterol against Freund's complete adjuvant (FCA)-induced arthritis in rats and found that taraxasterol at doses of 2, 4, and 8 mg/kg inhibited bone destruction by increasing serum OPG (osteoprotegerin) production and inhibiting the overproduction of serum inflammatory cytokines.

Taraxasterol, a pentacyclic-triterpene isolated from Taraxacum officinale, has been shown to have anti-inflammatory, anti-arthritic, neuroprotective, and anti-tumor effects. In vitro, taraxasterol inhibited IL-1β-induced NO and PGE₂ production in human osteoarthritic chondrocytes.

5.3 Liver Disease and Hepatoprotection

Evidence strength: Preclinical (rodent models, one cell-line study); no human clinical data.

One study explored the preventive effects of taraxasterol on concanavalin A (Con A)-induced acute hepatic injury in mice. It was found that treatment with taraxasterol significantly decreased the Con A-induced increase of liver index, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and hepatic malondialdehyde (MDA) levels, and increased the Con A-induced decrease of hepatic glutathione (GSH) and superoxide dismutase (SOD) production. Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, IFN-γ, and IL-4. In addition, treatment with taraxasterol alleviated hepatic histopathological injury and apoptosis induced by Con A.

In a study using acetaminophen (APAP) as the hepatotoxic agent, integrating network pharmacology with in vitro and in vivo experiments, the study indicated that taraxasterol inhibits APAP-stimulated oxidative stress, inflammatory response, and apoptosis in AML12 cells and mice by regulating the Nrf2/HO-1 pathway, JNK phosphorylation, and apoptosis-related protein expression. The in vitro findings showed that taraxasterol alleviated mitochondrial damage in AML12 cells treated with APAP. The in vivo results revealed that taraxasterol alleviated pathological changes in the livers of mice treated with APAP and inhibited the activity of serum transaminases.

In a liver fibrosis model, taraxasterol attenuated CCl₄-induced hepatocyte necrosis, inflammatory infiltration, and extracellular matrix (ECM) deposition. Taraxasterol inhibited the levels of ALT, AST, ALP, γ-GT, LN, HA, PC III, and IV-C in serum and TNF-α, IL-6, IL-1β, and MDA in liver. In addition, taraxasterol increased the activities of SOD and GSH-Px in liver.

Taraxasterol showed protective effects against ethanol-induced liver injury in mice by regulating the CYP2E1/Nrf2/HO-1 and NF-κB signaling pathways. Among the most relevant and predominant bioactive compounds of T. officinale, taraxasterol modulates inflammatory and oxidative stress pathways, helping to prevent liver damage.

5.4 Respiratory Conditions

Evidence strength: Preclinical (mouse models only); no human clinical data.

In vivo, taraxasterol was found to protect against LPS-induced acute lung injury and endotoxic shock in mice. Furthermore, taraxasterol has been reported to protect against OVA (ovalbumin)-induced allergic asthma in mice. These findings support a mechanistic link between taraxasterol's suppression of cytokine release and attenuation of pulmonary inflammation, but direct human evidence is absent.

5.5 Gastrointestinal Conditions (Colitis and Gastritis)

Evidence strength: Preclinical (cell culture and mouse models); no human clinical data.

In a study on ulcerative colitis, the optimal concentrations of LPS and taraxasterol for cell treatments in vitro were determined by MTT assay. A mouse model of colitis was established via dextran sodium sulfate (DSS) administration, and levels of IL-6 and TNF-α were detected through ELISA. ELISA results demonstrated that taraxasterol treatment decreased the expression levels of IL-6 and TNF-α in vitro and in vivo in a dose-dependent manner. TNF-α and IL-6 expression levels were lower in taraxasterol-treated groups compared with the UC model groups (P<0.01).

5.6 Cancer (Multiple Cancer Types)

Evidence strength: Preclinical (cell lines and xenograft mouse models); no human clinical data.

Taraxasterol is a pentacyclic triterpene isolated from Taraxacum officinale. Evidence indicates that taraxasterol possesses biological activities including anti-inflammatory and antitumor activity. Taraxasterol can suppress in vivo breast carcinogenesis and in vitro cell growth in colorectal cancer, cervical cancer, and melanoma.

Gastric cancer: A network pharmacology approach was applied to identify the collective targets of taraxasterol and gastric cancer. Nude mice were subcutaneously injected with MKN-28 cells to establish a gastric cancer subcutaneous xenograft model, which were treated with taraxasterol for 16 days. Tumor volume was then examined every other day. Pathological scoring was assessed using hematoxylin and eosin (H&E) staining, and expression levels of Ki-67 and the target genes of taraxasterol were confirmed by immunohistochemistry analysis.

Gastric cancer (glycolysis mechanism): Taraxasterol has been proved to exert anti-tumor functions in gastric cancer (GC), and work was carried out to identify the biological role of taraxasterol and molecular mechanisms underlying taraxasterol in the progression of GC.

Non-small cell lung cancer: Data demonstrated that taraxasterol inhibited the proliferation and migration of LLC and SPC-A1 cell lines in a time- and dose-dependent manner. Further study revealed that taraxasterol-mediated antitumor effects were achieved mainly by inducing tumor cell apoptosis and modulating the tumor microenvironment.

Prostate cancer: Taraxasterol could significantly suppress the viability and growth of androgen-independent prostate cancer cells and downregulate the expression of c-Myc and cyclin D1 in vitro. Mechanistically, the PI3K/AKT signaling pathway was weakened and the expression of FGFR2 was reduced after taraxasterol treatment in androgen-independent prostate cancer cells.

Colorectal cancer: Taraxasterol acetate targets RNF31 to inhibit RNF31/p53 axis-driven cell proliferation in colorectal cancer.

Melanoma: Studies showed that taraxasterol prevented the growth of melanoma cells by inhibiting the reactive oxygen species-mediated PI3K/Akt signaling pathway.

Hepatocellular carcinoma: Previous studies have shown that taraxasterol inhibits proliferation and induces apoptosis in HepG2 and Huh7 HCC cells.

Taraxasterol can inhibit tumor cell growth of many types of cancer including nasopharyngeal carcinoma, breast carcinoma, colon carcinoma, cervix carcinoma, and ovary carcinoma. Across all cancer studies, the evidence base is exclusively preclinical, and no human trials have been conducted or reported.

5.7 Neuroinflammation and Neuroprotection

Evidence strength: Preclinical (cell culture and rodent models); no human clinical data.

In one study, the anti-inflammatory effects and mechanism of taraxasterol were detected in LPS-stimulated BV2 microglia cells. The results showed that taraxasterol inhibited the LPS-induced inflammatory response in BV2 microglia cells by activating the LXRα–ABCA1 signaling pathway.

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), cause progressive damage to the nervous system. Reviews have explored whether taraxasterol has protective effects on neuronal death in neurodegenerative diseases. While mechanistic plausibility exists—particularly through NF-κB inhibition and antioxidant pathway activation—the evidence remains at the in vitro stage with very limited in vivo corroboration specific to isolated taraxasterol in neurodegeneration models.

5.8 Antioxidant Activity

Evidence strength: Preclinical; no human data.

In a study using bovine mammary epithelial cells (MAC-T) as a model, different concentrations of taraxasterol (0, 1, 5, 10, and 20 μg/mL) were used to protect against deoxynivalenol (DON)-induced cell damage. Taraxasterol at a concentration of 10 μg/mL significantly increased cell viability. Taraxasterol substantially decreased LDH release caused by DON, effectively alleviated the depletion of glutathione (GSH), the increase in lipid peroxidation of malondialdehyde (MDA), the reduction in total superoxide dismutase (T-SOD) activity, and the decrease in total antioxidant capacity (T-AOC) induced by DON. Taraxasterol also reduced the accumulation of reactive oxygen species (ROS).

6. Body Systems and Health Areas Associated with Taraxasterol

Taraxasterol is a natural pentacyclic triterpene primarily extracted from dandelion. Published pharmacological reviews give a general overview of the pharmacological activities of taraxasterol for treating various illnesses, such as respiratory, gastrointestinal, and urinary disorders.

• Hepatic system: Liver protection against toxic injury (ethanol, APAP, CCl₄, Con A); anti-fibrotic activity in animal models.
• Musculoskeletal / Immune system: Anti-arthritic effects in rheumatoid and adjuvant-induced arthritis models; suppression of the NLRP3 inflammasome.
• Respiratory system: Taraxasterol was found to protect against LPS-induced acute lung injury and endotoxic shock in mice.
• Gastrointestinal system: Activity in models of ulcerative colitis and gastritis via cytokine suppression.
• Oncology: In animal or cellular models, taraxasterol has been shown to have significant preventive and therapeutic effects in liver damage, gastritis, colitis, arthritis, pneumonia, tumors, and immune system diseases.
• Nervous system: Anti-neuroinflammatory effects in microglia cell models via LXRα-ABCA1 and NF-κB pathways.
• Immune system: Earlier work demonstrated that taraxasterol possesses anti-inflammatory and immunomodulatory effects in vivo and in vitro.

7. Dosage Forms and Dosages Reported in Studies

All dosages below are reported exactly as stated in peer-reviewed sources and pertain exclusively to preclinical (animal or cell) studies. No established human dosage has been determined.

• LPS-induced endotoxic shock (mice, in vivo): 2.5, 5, and 10 mg/kg administered over 36 hours produced survival rates of 30%, 40%, and 70%, respectively.
• Collagen-induced arthritis (CIA mice, in vivo): 10 mg/kg was used in CIA mice, alongside doses of 0.3 to 0 μm in HFLS-RA cells.
• Freund's complete adjuvant arthritis (rats, in vivo): Doses of 2, 4, and 8 mg/kg inhibited bone destruction and suppressed inflammatory cytokines.
• Ear edema inflammation (mice, in vivo): The ID₅₀ of taraxasterol in TPA-induced mouse ear edema was 0.3 mg/ear.
• Propionibacterium acnes-induced ear edema (mice, in vivo): 10 mg/kg improved inflammatory responses in a mouse ear edema model.
• Ulcerative colitis (mice, in vivo): The 100 mg/kg treatment group showed significantly lower levels of TNF-α and IL-6 than the 25 mg/kg treatment group.
• Bovine mammary epithelial cells (in vitro): Concentrations of 0, 1, 5, 10, and 20 μg/mL were tested; 10 μg/mL significantly increased cell viability against DON-induced injury.
• Pharmacokinetic study (rats, oral): A pharmacokinetic study of taraxasterol was conducted after oral administration of 7.75, 15.5, and 31.0 mg/kg in rats.

8. Safety Considerations and Interactions

8.1 Preclinical Safety Signals

No toxic effects of taraxasterol were observed in mice that received doses as high as 10 mg/kg. Additional research is also necessary to identify the effective concentration of taraxasterol in plasma.

More clinical studies are necessary on the metabolism, bioavailability, and safety of taraxasterol to support its applications in pharmaceuticals and medicine.

8.2 Pharmacokinetics: Current State of Knowledge

Zhang et al. reported that the amount of taraxasterol in the plasma of rats following oral administration could be accurately detected through a highly selective and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. This finding may aid in the pharmacokinetic study of taraxasterol in humans and other animals.

The LC/MS/MS method developed for rat plasma was validated across a quantification range of 9.0–5000 ng/mL. The mean recoveries of taraxasterol in rat plasma ranged from 85.3 to 87.2%, and the matrix effects for taraxasterol were between 98.5 and 104.0%. This establishes a methodological foundation for future pharmacokinetic research, but human PK data remain unpublished.

8.3 Regulatory and Evidence Gaps

The European Medicines Agency (EMA) has indicated that pharmacodynamic and pharmacokinetic data regarding Taraxacum herbal substances/preparations are not yet available. Furthermore, studies for clinical efficacy and dose response were not found, and information on posology and duration of use, or clinical studies in special populations such as the elderly and children, are not available.

More clinical studies are necessary on the metabolism, bioavailability, and safety of taraxasterol to support its applications in pharmaceuticals and medicine. The compound is present in food-grade dandelion preparations that have long histories of safe use in human diets, but isolated taraxasterol as a concentrated supplement has no established safety profile in human populations based on formal clinical studies.

8.4 Potential Interactions and Cautions

Because all pharmacological data on taraxasterol are preclinical, the following interaction considerations are derived from mechanistic inference from the reported pathways. Taraxasterol has been reported to possess several medicinal properties and to modulate several biochemical and metabolic signaling pathways as a means of exerting its pharmacological effects. The compound modulates the NF-κB, MAPK, PI3K/Akt, Nrf2/HO-1, TLR4, and Wnt/β-catenin pathways—all of which are targets of various clinically used drugs. Formal drug-interaction studies in humans have not been conducted or published as of the most recent literature reviewed (2024).

The EMA indicates that pharmacodynamic and pharmacokinetic data regarding this herbal substance/preparation are not yet available. Accordingly, specific interaction warnings with pharmaceutical drugs cannot be stated with evidence-based confidence, and this remains an active gap in the research literature.

9. Summary of Evidence Status

Reviews aim to evaluate the current state of research and provide an overview of the possible applications of taraxasterol in various diseases. The reported phytochemical properties and pharmacological actions of taraxasterol, including anti-inflammatory, anti-oxidative, and anti-carcinogenic properties, and its potential molecular mechanisms in developing these diseases, have been highlighted.

Even though some biological effects have been ascribed to taraxasterol, it is still being explored for more therapeutic benefits. The totality of the current evidence base presents taraxasterol as a phytochemically well-characterized pentacyclic triterpenoid with robustly replicated anti-inflammatory, antioxidant, and preliminary anticancer activity across multiple preclinical model systems. The mechanistic data are detailed and internally consistent. However, the complete absence of human clinical trial data means that no therapeutic indication, effective dose, or clinical safety profile can be established for taraxasterol as an isolated ingredient in humans. Translation from preclinical findings to clinical application represents the primary outstanding scientific challenge in this field.

References

• Jiao F, et al. "The phytochemical and pharmacological profile of taraxasterol." Frontiers in Pharmacology (2022). PMC9386448.
• Jiao F, et al. "The phytochemical and pharmacological profile of taraxasterol." PubMed Abstract. PMID 35991893.
• Obafemi OT, et al. "Pharmacological relevance of taraxasterol: A review." Pharmacological Research – Modern Chinese Medicine (2024).
• Wu J, et al. "Botany, Traditional Use, Phytochemistry, Pharmacology and Quality Control of Taraxaci herba: Comprehensive Review." Pharmaceuticals (Basel) (2024). PMC11434673.
• Taraxasterol | C30H50O | CID 115250 – PubChem (NIH).
• Taraxasterol – Wikipedia (for biosynthesis pathway details).
• Gu M, et al. "Taraxasterol Inhibits Tumor Growth by Inducing Apoptosis and Modulating the Tumor Microenvironment in Non-Small Cell Lung Cancer." PMC9562636.
• Taraxasterol suppresses cell proliferation and boosts cell apoptosis via inhibiting GPD2-mediated glycolysis in gastric cancer. PMC8554918.
• Chen W, et al. "Network pharmacology-based identification of the antitumor effects of taraxasterol in gastric cancer." PMC7378706.
• Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway. PMC10421874.
• Taraxasterol prompted the anti-tumor effect in mice burden hepatocellular carcinoma by regulating T lymphocytes. PMC9110731.
• Taraxasterol Inhibits LPS-Induced Inflammatory Response in BV2 Microglia Cells by Activating LXRα. PMC5893773.
• In vivo anti-inflammatory effects of taraxasterol against animal models. PMC5411885.
• Anti-inflammatory and anti-apoptosis activity of taraxasterol in ulcerative colitis in vitro and in vivo. PMC6676081.
• Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-κB and Bax/Bcl-2 signalling pathways. Artificial Cells, Nanomedicine, and Biotechnology (2019).
• Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in vitro and in vivo experiments. PubMed PMID 37209606.
• Protective Effects of Taraxasterol against Deoxynivalenol-Induced Damage to Bovine Mammary Epithelial Cells. PMC8948886.
• Zhang H, et al. "Quantification of taraxasterol in rat plasma by LC/MS/MS: application to a pharmacokinetic study." Biomedical Chromatography (2015).
• Phytochemical Investigations on Chemical Constituents of Taraxacum bessarabicum. PMC6487403.
• Multilateral Use of Dandelion in Folk Medicine of Central-Eastern Europe. PMC11723127.
• Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. PMC11054461.
• New prospects in oncotherapy: bioactive compounds from Taraxacum officinale. PMC12334242.
• Taraxasterol – ScienceDirect Topics Overview.
• The Role of Dandelion (Taraxacum officinale) in Liver Health and Hepatoprotective Properties. PMC12299503.